Double times of autologous peripheral blood stem cell transplantation to treat multiple myeloma.
- Author:
Xiao-Rong ZHANG
1
;
Li-Ping SU
;
Lian-Rong XU
;
Qiu-Juan ZHU
Author Information
1. Department of Hemotology, The Second Hospital, Shanxi Medical University, Taiyuan 030001, China.
- Publication Type:Case Reports
- MeSH:
Female;
Humans;
Middle Aged;
Multiple Myeloma;
therapy;
Peripheral Blood Stem Cell Transplantation;
methods;
Transplantation, Autologous
- From:
Journal of Experimental Hematology
2007;15(4):866-869
- CountryChina
- Language:Chinese
-
Abstract:
In order to explore the security and feasibility of double autologous peripheral blood stem cell transplantation (APBSCT) for treatment of multiple myeloma, a 49 years old female patient with multiple myeloma was therapied with double APBSCT. The first peripheral blood stem cell (PBSC) mobilization regimen included CTX 2 g/m(2) x 1d and G-CSF [10 microg/(kgxd)] x 5 d. The conditioning regimen was given melphalan 200 mg/m(2). The transplanted number of mononuclear cells was 6.1 x 10(8)/kg and that of CD34(+) cells was 4.7 x 10(6)/kg. The second APBSCT was performed six months later. PBSC mobilization regimen was G-CSF [10 microg/(kgxd)] x 5 d. The conditioning regimen was melphalan 200 mg/m(2). The transplanted number of mononuclear cells was 10.2 x 10(8)/kg and that of CD34(+) cells was 5.9 x 10(6)/kg. The results showed that the absolute neutrophil count (ANC) rose to above 0.5 x 10(9)/L on day 17 and platelet count exceeded 20 x 10(9)/L on day 15 after first transplantation. After second transplantation ANC rose to above 0.5 x 10(9)/L on day 22 and platelet count exceeded 20 x 10(9)/L on day 13. There were neither obvious adverse reaction nor severe complication during the double transplantations. The patient's ostealgia and anemia were healed through above therapy. In the follow-up of 7 months, the patient's general status was good and she remained in complete remission phase. It is concluded that double APBSCT is safe, effective and feasible for the treatment of multiple myeloma.
